期刊文献+

左旋氨氯地平联合替米沙坦治疗2型糖尿病高血压疗效观察 被引量:1

暂未订购
导出
摘要 目的:探讨单用左旋氨氯地平、替米沙坦与两药合用治疗2型糖尿病高血压患者的有效性及安全性。方法:2006年1月—2009年12月入选268例2型糖尿病高血压患者,随机分为A,B,C组,3组患者均口服降糖药,少数患者皮下注射胰岛素控制血糖,入选者在用药前停用其他降压药1周。A组:左旋氨氯地平2.5~5.0 mg,每日1次;B组:替米沙坦40 mg,每日1次;C组:左旋氨氯地平2.5 mg,每日早上1次,替米沙坦20~40 mg,每日晚上1次。治疗4~6周血压平稳,连续观察3个月,每日监测血压、心率,观察不良反应情况。结果:A组89例,平均年龄(61±8)岁,总有效率67.4%;B组89例,平均年龄(60±7)岁,总有效率60.6%;C组90例,平均年龄(59±9)岁,总有效率80%。3组相比,C组总有效率高,副作用少。结论:左旋氨氯地平联合替米沙坦治疗2型糖尿病高血压患者安全、有效、耐受性好。
作者 蔚珍
出处 《临床医药实践》 2010年第5期340-341,共2页 Proceeding of Clinical Medicine
  • 相关文献

参考文献3

二级参考文献33

  • 1中国居民营养与健康现状[J].中国心血管病研究,2004,2(12):919-922. 被引量:493
  • 2刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2611
  • 3卫生部心血管病防治研究中心.中国心血管病报告2006.北京:中国大百科全书出版社,2007.
  • 4Liu L, Zhang Y, Liu G, et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long- term placebo-controlled trial in Chinese hypertensive patients. J Hypertens, 2005,23 : 2157-2572.
  • 5Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004,363:2022-2031.
  • 6Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet ,2003,361 : 1149-1158.
  • 7Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press ,2007,16 : 13-19.
  • 8Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers : a quantitative overview. Hypertension, 2007,50 : 181 - 188.
  • 9Makino H, Haneda M, Babazono T, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes : a post-hoc analysis of The Incipient to Overt: Angiotensin Ⅱ Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res,2008,31:657-664.
  • 10Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase Ⅲ, 12-week, muhicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed- dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage Ⅱ hypertension. Clin Ther, 2007,29 : 2667 -2676.

共引文献190

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部